Diabetes Technology Updates From ATTD 2025: Bi-Hormonal Closed-Loop Systems, Continuous Ketone Monitors & Cell Based Therapy for Type 1 Diabetes
Endocrinologists Dr. Steve Edelman and Dr. Jeremy Pettus share most significant diabetes breakthroughs from the ATTD 2025 Diabetes Congress in Amsterdam
In this video you will learn about:
✔ The debate on using “time in tight range” (70-140 mg/dL) vs. standard time in range (70-180 mg/dL) for CGM metrics
✔ Abbott’s upcoming continuous ketone monitor that measures both glucose and ketones with 14-day wear
✔ Extensive data supporting hybrid closed loop systems across diverse patient populations with improved outcomes
✔ Progress toward fully closed loop systems that don’t require meal announcements
✔ Teplizumab (Tzield) showing promise for newly diagnosed Type 1 patients in the PROTECT study
✔ Vertex’s advancing cellular therapy using stem cell-derived islet cells for patients with severe hypoglycemia
Diabetes technology is advancing at breakneck speed. Drs. Edelman and Pettus, both Type 1 patients themselves, highlight game-changing developments from Amsterdam: Abbott’s upcoming dual glucose-ketone monitor for early DKA detection, hybrid closed loop systems moving toward fully automated insulin delivery without meal announcements, and promising bi-hormonal systems adding glucagon to prevent lows. Meanwhile, Teplizumab shows exciting potential for preserving insulin production in newly diagnosed Type 1s, while Vertex’s stem cell-derived islet therapy nears completion of initial trials, offering hope for those with severe hypoglycemia—all signaling we’re entering a new era in diabetes care.
LEARN MORE ABOUT THIS TOPIC
Highlights from the Recent Diabetes Technology Meetings in Europe (ATTD 2024)
Join us as we talk about our experience at the 18th Annual Diabetes Technology Meeting in Europe (ATTD 2024). In this podcast, we’ll be unpacking our favorite lectures from the event, which hold some very exciting data and insights. From cutting-edge advancements in diabetes technology to the latest developments in medications, we’ll cover it all. Tune in as we explore the forefront of diabetes innovation and share our experiences from this meeting!
FDA Denies SGLT Drug, Dexcom + Oura Ring, Abbott's Ketone Monitor, Medtronic KLUE
Watch Dr. E take on the FDA (spoiler: it didn’t end well) over their controversial SGLT inhibitor denial for Type 1 diabetes. Discover why Dexcom and Oura Ring are the new power couple of diabetes tech, geek out over Abbott’s groundbreaking dual glucose-ketone monitor, and learn how Medtronic’s new Klue smartwatch can tell when you’re sneaking that midnight snack (and bolus for it too!). With their signature mix of cutting-edge information and slightly inappropriate jokes, this episode delivers the diabetes news you need in that signature entertaining TCOYD style.
Insulin was found to be effective for diabetes in 1922. My grandfather was one of the first users. It’s now 2025. We’re still not past insulin. I take it now.
Find a cure!!! It’s been 100 years!!!!
Lots of people are working hard on it! That’s so amazing that your grandfather was one of the first people on insulin!
I’m certain there is a cure already for diabetes and cancer but releasing it would take away the billions of dollars that pharmaceutical companies and Doctors make along with many jobs. The money that is donated to finding a cure for diabetes alone would blow our minds.
The increase in diabetes and cancer over the last 10 years is astronomical. I guarantee they won’t release any cures. Greed is real!
*a Mother of a Type 1 diabetic teen*
Thanks for your comment – all of us at TCOYD hope your child is doing well and has access to good care.
You said it, 100% right. They introduce new technology only to make more money. Try finding a cure. Greed won’t let that happen. They want our kids sick with diabetes for the rest of their lives cause it’s BIG MONEY
No negative comments for me. It’s amazing the advancements. I’m type 1 now 14 years. I hope in my life there will be a complete closed loop system. Run automatically like a real pancreas. Thank you very much for your video and information!
Thanks Robert! Appreciate it!
I am T2 with 1 positive antibody (my endo tested for 2 of them-not 4-a couple years ago.) I had 1 T1 parent (diagnosed in adulthood when I was around 10) and 1 T2 parent. Almost all extended family are diabetic. When I read about the drug that delays onset of T1 in The NY Times and asked about it, I was told it’s too late for me, my diabetes is too far advanced. But if Tzield can be used for T1, maybe it can also help me? Should I ask my dr again? (Endo also tests insulin levels periodically and last time they were in the low end of the range but had not changed from the previous test).
Just to be sure, ask your doctor to test for the set of four type 1 diabetes autoantibodies. If you already have diabetes, even if you were diagnosed with type 1 you would be in stage 3, and Tzield is currently only indicated for stage 2. But it would be important to know if you have type 1 or type 2.
Thank you
Thanks you for sharing such upside news. I anxiously await some developments assisting T1D
We do too – thanks Dennis!
Very interesting. How do I join?
If you are inquiring about the Vertex study, you can apply here: https://880.t1dstudy.com/